Twist Bioscience CEO sells 4,548 shares under plan

Q: How many TWST shares did Emily M. Leproust sell, and at what prices?

Emily M. Leproust reported direct sales of 4,548 Twist Bioscience common shares on October 5, 2026, across eight entries, with weighted-average sale prices ranging from $200.4379 to $207.4556 per share. The sales were made under a Rule 10b5-1 trading plan adopted June 15, 2026.

Q: What vesting terms were reported for Emily M. Leproust's TWST options?

The option covering 131,290 shares vested 25% on October 24, 2020, with 1/48th vesting on each monthly anniversary thereafter, subject to continuous service. The 64,950-share performance option vested and became exercisable on December 19, 2022, after the applicable performance criteria were met.

The Chief Executive Officer's sales were made under a Rule 10b5-1 trading plan adopted June 15, 2026.

Filing Impact

(High)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Twist Bioscience Corp (TWST) Chief Executive Officer Emily M. Leproust reported direct sales of 4,548 common shares on October 5, 2026, across eight entries. The entries list weighted-average sale prices from $200.4379 to $207.4556 per share; the sales were made under a Rule 10b5-1 trading plan adopted June 15, 2026. She also reported employee stock options covering 131,290 common shares at a $23.33 exercise price, expiring October 23, 2029, and options covering 64,950 shares at $67.85, expiring August 31, 2030.

Insights

Analyzing...

Insider Trade Summary 10b5-1

Net Seller: 4,548 shares

Net Sell 10 txns

Insider Leproust Emily M.

Role Chief Executive Officer

Sold 4,548 shs ($919K)

Type	Security	Shares	Price	Value
Sale	Common Stock ^{F1, F2}	1,840	$200.4379	$369K
Sale	Common Stock ^{F1, F3}	481	$201.2556	$97K
Sale	Common Stock ^{F1, F4}	1,017	$202.3236	$206K
Sale	Common Stock ^{F1, F5}	432	$203.6072	$88K
Sale	Common Stock ^{F1, F6}	290	$204.7996	$59K
Sale	Common Stock ^{F1, F7}	297	$205.7772	$61K
Sale	Common Stock ^{F1, F8}	146	$206.8449	$30K
Sale	Common Stock ^{F1, F9}	45	$207.4556	$9K
holding	Employee Stock Option (right to buy) ^F10	--	--	--
holding	Employee Stock Option (right to buy) ^F11	--	--	--

Holdings After Transaction: Common Stock — 562,760 shares (Direct); Employee Stock Option (right to buy) — 196,240 contracts (Direct)

Footnotes (11)

F1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026.
F2. Represents the weighted average sales price per share. The shares sold at prices ranging from $200 to $200.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3. Represents the weighted average sales price per share. The shares sold at prices ranging from $201 to $201.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F4. Represents the weighted average sales price per share. The shares sold at prices ranging from $202 to $202.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F5. Represents the weighted average sales price per share. The shares sold at prices ranging from $203.29 to $203.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F6. Represents the weighted average sales price per share. The shares sold at prices ranging from $204.33 to $205.32 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F7. Represents the weighted average sales price per share. The shares sold at prices ranging from $205.37 to $206.34 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F8. Represents the weighted average sales price per share. The shares sold at prices ranging from $206.38 to $207.33 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F9. Represents the weighted average sales price per share. The shares sold at prices ranging from $207.38 to $207.8 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F10. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
F11. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.

Key Figures

Common shares sold: 4,548 shares Weighted-average sale price: $200.4379 per share Weighted-average sale price: $207.4556 per share +2 more

5 metrics

Common shares sold 4,548 shares Eight direct sale entries on October 5, 2026

Weighted-average sale price $200.4379 per share 1,840-share entry on October 5, 2026

Weighted-average sale price $207.4556 per share 45-share entry on October 5, 2026

Option underlying shares 131,290 shares $23.33 exercise price; expiration October 23, 2029

Option underlying shares 64,950 shares $67.85 exercise price; expiration August 31, 2030

Key Terms

Rule 10b5-1 trading plan, weighted average sales price per share, performance stock options

3 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

performance stock options financial

"Represents performance stock options granted to the reporting person"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TWST shares did Emily M. Leproust sell, and at what prices?

Emily M. Leproust reported direct sales of 4,548 Twist Bioscience common shares on October 5, 2026, across eight entries, with weighted-average sale prices ranging from $200.4379 to $207.4556 per share. The sales were made under a Rule 10b5-1 trading plan adopted June 15, 2026.

What vesting terms were reported for Emily M. Leproust's TWST options?

The option covering 131,290 shares vested 25% on October 24, 2020, with 1/48th vesting on each monthly anniversary thereafter, subject to continuous service. The 64,950-share performance option vested and became exercisable on December 19, 2022, after the applicable performance criteria were met.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/07/2026 - 04:05 PM Accepted by SEC EDGAR 10/07/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leproust Emily M.

(Last)

(First)

(Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD.

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/05/2026		S⁽¹⁾		1,840	D	$200.4379⁽²⁾	565,468	D
Common Stock	10/05/2026		S⁽¹⁾		481	D	$201.2556⁽³⁾	564,987	D
Common Stock	10/05/2026		S⁽¹⁾		1,017	D	$202.3236⁽⁴⁾	563,970	D
Common Stock	10/05/2026		S⁽¹⁾		432	D	$203.6072⁽⁵⁾	563,538	D
Common Stock	10/05/2026		S⁽¹⁾		290	D	$204.7996⁽⁶⁾	563,248	D
Common Stock	10/05/2026		S⁽¹⁾		297	D	$205.7772⁽⁷⁾	562,951	D
Common Stock	10/05/2026		S⁽¹⁾		146	D	$206.8449⁽⁸⁾	562,805	D
Common Stock	10/05/2026		S⁽¹⁾		45	D	$207.4556⁽⁹⁾	562,760	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (right to buy)	$23.33							⁽¹⁰⁾	10/23/2029	Common Stock	131,290		131,290	D
Employee Stock Option (right to buy)	$67.85							12/19/2022	08/31/2030	Common Stock	64,950		64,950⁽¹¹⁾	D

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026.

2. Represents the weighted average sales price per share. The shares sold at prices ranging from $200 to $200.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

3. Represents the weighted average sales price per share. The shares sold at prices ranging from $201 to $201.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

4. Represents the weighted average sales price per share. The shares sold at prices ranging from $202 to $202.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

5. Represents the weighted average sales price per share. The shares sold at prices ranging from $203.29 to $203.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

6. Represents the weighted average sales price per share. The shares sold at prices ranging from $204.33 to $205.32 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

7. Represents the weighted average sales price per share. The shares sold at prices ranging from $205.37 to $206.34 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

8. Represents the weighted average sales price per share. The shares sold at prices ranging from $206.38 to $207.33 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

9. Represents the weighted average sales price per share. The shares sold at prices ranging from $207.38 to $207.8 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

10. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.

11. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Emily M. Leproust	10/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR